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Abstract
Fragment-based screening has evolved as a remarkable approach within the drug discovery process both in the industry 
and academia. Fragment screening has become a more structure-based approach to inhibitor development, but also towards 
development of pathway-specific clinical probes. However, it is often witnessed that the availability, immediate and long-
term, of a high quality fragment-screening library is still beyond the reach of most academic laboratories. Within iNEXT 
(Infrastructure for NMR, EM and X-rays for Translational research), a EU-funded Horizon 2020 program, a collection of 
782 fragments were assembled utilizing the concept of “poised fragments” with the aim to facilitate downstream synthesis 
of ligands with high affinity by fragment ligation. Herein, we describe the analytical procedure to assess the quality of this 
purchased and assembled fragment library by NMR spectroscopy. This quality assessment requires buffer solubility screening, 
comparison with LC/MS quality control and is supported by state-of-the-art software for high throughput data acquisition 
and on-the-fly data analysis. Results from the analysis of the library are presented as a prototype of fragment progression 
through the quality control process.
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Introduction
Fragment-based screening by NMR has evolved as a remark-
able approach within the drug discovery process 25 years 
after the proposal of this approach (Shuker et al. 1996). 
Since then, fragment-based drug discovery (FBDD) has 
been an important tool in identifying initial hits against dif-
ficult targets and thereby has become one of the foremost 
and popular methods to be used within the pharmaceutical 
and biotechnology industry (Baker 2013; Murray and Rees 
2009). Vemurafinib from Plexxicon, developed as an anti-
melanoma, was the first approved drug using FBDD (Tsai 
et al. 2008) and followed by several others which are now 
either approved drugs or in the different phases of clinical 
trials (Brough et al. 2008; Erlanson et al. 2020; Howard et al. 
2009; May et al. 2011; Park et al. 2008; Wang et al. 2010; 
Woodhead et al. 2010; Wyatt et al. 2008; Zhu et al. 2010).
FBDD has not only become a widely used technology in 
industry but has been also successfully adopted in academia 
(Bulfer et al. 2016). Historically, academic institutes have 
been recognized as screening centers involved in developing 
tool compounds for genomic studies. In this context large 
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chemical libraries were introduced which further strength-
ened the academic screening campaigns. From thereon 
academia has ventured into more challenging translational 
projects, in particular addressing the “undruggable” target 
classes and rare diseases. In comparison to high-throughput 
screening (HTS), the advantage of FBDD has been realized 
early on. FBDD uses only a few thousand fragments and 
there by rendering the approach economically affordable. 
Further, the necessary knowhow and the required infrastruc-
ture for performing FBDD (e.g., NMR spectrometers and 
other instruments) are becoming more and more available 
at most academic institutes worldwide.
Generally, it has been realized that after a very enthusi-
astic start of FBDD within academia, soon it becomes an 
uphill task as these projects enter advanced stages of the 
drug discovery unlike the industry-based screening cam-
paigns. One of the major struggles within academia-based 
drug discovery is to develop an initial fragment hit to a lead 
and drug candidate. In this context, the limited availability 
of high-quality chemical libraries for academia narrows the 
chances of discovering specific leads which can be devel-
oped into a drug candidate. The former challenge has been 
overcome by initiating large consortiums involving several 
academic institutes which work like a “gear-box” and assem-
bles the necessary manpower, materials and instrumenta-
tion and strive towards translational research. The latter 
challenge involving the fragment libraries proves to be one 
of the major hurdles partly attributed to the fact that the 
pharmaceutical and biotechnology companies developed 
and maintained their own specific libraries which were not 
publicly available. Academic institutes generally resorted 
to commercial vendors such as Maybridge, Chembridge, 
Enamine, F2X-universal library, LiverpoolChiroChem, JBS 
FragXtal screen and the MedChemExpress fragment library 
and many others (Lepre 2011). Fragment libraries comprive 
low molecular weight compounds up to a molecular weight 
of 300 Da. One of their primary requirements is structural 
diversity to sample a large chemical and structural space. 
However, most of the commercially available libraries hosts 
very large sets of fragments with low diversity, issues with 
solubility or reactivity and therefore may not be suitable 
for pursuing a screening project within the timeframe of 
an academic environment. Another challenge which most 
of these libraries posed is their quality (purity and chemi-
cal identity) and also the chemical properties needed for 
downstream chemistry to pursue either fragment-linking or 
-growing chemical campaigns with the aim of developing 
high affinity inhibitors.
We are partners of the iNEXT (Infrastructure for NMR, 
EM and X-rays for Translational research) consortium, a 
European facility network to stimulate translational struc-
tural biology (iNext Consortium 2018). Within the design 
of structure-guided drug discovery workflows, iNEXT 
contributed to FBDD by assembling and validating a frag-
ment library. After careful computational analysis of a large 
collection of fragments (11,677 in total), a total of 782 frag-
ments were filtered and selected with the aim of “minimum 
fragments and maximum diversity” to cover a large chemical 
space and in particular based on the concept of “poised frag-
ments” with the aim to streamline downstream synthesis of 
more complex and high affinity ligands (Cox et al. 2016). 
These individual fragments were then purchased from vari-
ous vendors and assembled.
Quality control of the fragment library is an important 
and indispensable prior and periodical requirement for pur-
suing screening measurements (Dalvit et al. 2006). Previ-
ously, many researchers have extensively reported several 
measures to be taken in assessing the quality of a fragment 
library (Bentley et al. 2018; Dalvit et al. 2006; Gossert and 
Jahnke 2016; Lepre 2011; Taylor et al. 2018). Importantly, 
most of these analyses were based on 1D proton NMR spec-
tra. However, there is little information across the literature 
pertaining to a detailed presentation of the quality control 
process and were mostly based on a single biophysical tech-
nique in determining the quality of the fragments. Further, 
although considerable research has been devoted to qual-
ity assessment of the fragments, rather less attention has 
been paid to the speed of the assessing protocol. In order 
to close-in this gap, we present here an integrated approach 
using commercially available state-of-the-art software Com-
plete Molecular Confidence for quantification (CMC-q) and 
CMC-assist (CMC-a) developed by the company Bruker, 
1H-NMR measurements and liquid chromatography-mass 
spectrometry (LC/MS) for characterization of the integ-
rity and solubility of the fragments. CMC-q and CMC-a 
efficiently facilitate automated NMR-data acquisition and 
“on-the-fly” analysis and extract information from complex 
NMR data, conduct consistency and concentration assess-
ments. Manual cross-validation of the automated NMR 
software-based quality assurance results together with the 
LC–MS data was performed for a subset of the fragment 
library. Approximately 30% of the purchased fragments do 
not pass the QC and had to be discarded.
Chemical quality of the library
The design principle of a fragment library holds the key 
for any successful screening campaign. The iNEXT frag-
ment library was collected using the initial library of “poised 
fragments” (fragments contain at least one functional group 
which can be synthesized using a robust, well-character-
ized reaction). The principle of building and designing such 
library is described previously (Cox et al. 2016).
In order to estimate the chemical diversity of the library, 
we performed a molecular clustering analysis of the library 
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using the Knime analytics platform (www.knime .com). The 
protocol workflow (provided in the Supp. Mat.) of the clus-
tering was performed using the FCFP4 fingerprints (Rogers 
and Hahn 2010) with a Tanimoto distance matrix calcula-
tion followed by a hierarchically clustering of the distance 
matrix (Threshold of 0.6 to assign a member to a cluster). 
For the 782 compounds (Supplementary excel sheet), a total 
of 391 distinguished chemical clusters were found, 198 clus-
ters contain only a single molecule. The clustering analysis 
suggests a high chemical diversity of the library with a high 
number of fragments belonging to clusters with 1, 2 or 3 
members (Fig. 1a). Examples of molecular clusters are also 
shown in Fig. 1b and all class IDs and class size are reported 
in the excel file (Supp. Material).
To assign the drug likeliness of the library, many com-
mon molecular descriptors were calculated (see Knime 
protocol and excel Table in Supp. Mat.). The analysis of 
molecular weight indicates that around 80% of the frag-
ments are in the range 200–250 Da with hydrogen-bond 
donor and hydrogen-bond acceptor atoms below three, 
which clearly satisfies the widely adopted “rule of 3” guide 
(Congreve et al. 2003; Jhoti et al. 2013).
Since all the fragments comply with the Lipinski rule 
of 5, we further investigated drug-likeness of the library 
by calculating the quantitative estimate of drug-likeness 
(QED) of all the molecules. The concept of QED was 
introduced by Bickerton et al. (2012) to reflect the under-
lying distribution of molecular properties and quantify 
the drug-likeness. The QED with the optimal 1000 weight 
combinations that give the highest information content 
(QEDw, mo) was calculated for all the fragments using 
the equation reported in the above article and the values 
are listed in Table (Supp. Mat.).
The calculated QED values range from 0.36 to 0.9 with 
an average value of 0.77. The highest value indicates the 
most drug-like molecule. 94% of the fragments have a 
value of QED higher than 0.6 and 44% of the fragments 
have a value higher than 0.8 indicating a large number of 
Fig. 1  Chemical clustering of 
the iNEXT-fragment library. a 
Cluster size versus cluster ID 
(on the top right, an example 
of compounds belonging to 
cluster number 301 with five 
class members). b Examples for 
molecular clusters with 1, 2, 3 
and 4 members
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the molecules in the library that can be potentially ini-
tiators of a drug candidate (according to QED concept) 
(Table 1).
The QED equation contains a contribution term used for 
the number of unwanted substructures that can be related to 
compound stability, reactivity or toxicity. Using a substruc-
ture filter of the unwanted substructures listed in the Bick-
erton’s article, 111 compounds (14% of the library) were 
found to have one or more of the unwanted substructures 
and mostly not very dramatic ones (Table 2). The average 
QED of this set of compounds is 0.68 showing a low weight 
given to the unwanted substructure alerts in the calculation.
This simple analysis of molecular clusters and QED 
underlines the fact that the iNEXT fragment library is rela-
tively of high quality in its composition and can be used 
for FBS with a higher chance to identify drug like lead 
candidate.
Fragment purchase, stock preparation 
and storage
A carefully crafted library is a prerequisite for its durability 
and progression of over several screening campaigns. Typi-
cally, there could arise several practical scenarios during 
the purchase, stock solution preparation and assembly of 
compounds (Lepre 2011). In general, if the vendor provides 
a certificate with the exact amount of compound delivered in 
the vial, one could directly add the exact volume of solvent 
to attain a desired concentration and avoid the much labori-
ous procedure of weighing and dissolving. DMSO, although 
being a mild oxidant of some compounds (Prochazkova et al. 
2012), is in general the solvent of choice for the prepara-
tion of the stock solutions. Typical storage conditions for 
the fragment libraries is between 4 and − 20 °C in order to 
avoid any degradation of the compounds over time. How-
ever, repeated freeze–thaw cycles can result in degradation 
of some compounds and also DMSO being hygroscopic can 
introduce atmospheric water into the stock solutions, thus 
varying the stock concentration. Addition of 10% water pre-
vents the freezing of the DMSO solution at 4 °C and thus 
overcomes the freeze–thaw problems (Gossert and Jahnke 
2016). Considering all of the above facts, the iNEXT library 
was assembled by purchasing selected fragments from sev-
eral vendors, which were dissolved and stored as 50 mM 
stock solutions in a mixture of 90% d6-DMSO and 10%  D2O. 
Freshly prepared stocks were dispensed and stored at 4 °C in 
V-bottom 0.75 ml 2D-barcoded tubes (Matrix Cat. No 3731) 
covered with SepraSeal septum caps (Matrix Cat. No 4463).
Fragment characterization: methods 
of choice for quality control
A careful determination of ligand integrity and solubility 
under the given condition is one of the prime aims within the 
quality control of the fragment library. Some of the meas-
ures taken to ensure the quality of the fragments have been 
elegantly discussed and described previously in the literature 
(Gossert and Jahnke 2016). We used an integrated approach 
utilizing the software Complete Molecular Confidence for 
quantification (CMC-q) and CMC-a, 1H-NMR experiments 
and liquid chromatography-mass spectrometry for charac-
terization of the integrity and solubility of the fragments. 
CMC-q is an automation software module within Topspin 
for data acquisition, processing, analysis and quantification 
of small molecules by NMR spectroscopy. CMC-a is a soft-
ware tool for interactive, assisted data analysis. It processes 
Table 1  The average values of the molecular descriptors used for the 
calculation of the QED
Molecular descriptors Mean
Molecular weight 219.80
SlogP 1.59
Number of hydrogen bonds donors 2.79
Number of hydrogen bonds acceptors 1.27
Topological polar surface area 55.36
Number of rotatable bonds 2.60
Number of aromatic rings 1.43
Number of unwanted substructure alerts 0.17
QED 0.77
Table 2  Number of compounds with unwanted substructures accord-
ing to Bickerton et al.
Unwanted substructures (Usub) Number of 
compounds with 
Usub
2-Halo pyridine 2
Acyl hydrazine 7
Aliphatic long chain 1
Aniline 37
Catechol 9
Cumarine 3
Cyanamide 2
Hydantoin 3
Hydrazine 8
Hydroquinone 7
Hydroxamic acid 3
Mercapto-1,3,4- thiadiazole 5
Oxygen–nitrogen single bond 29
Phenol ester 5
Thiocarbonyl group 11
Triple bond 9
Journal of Biomolecular NMR 
1 3
all 1D and 2D NMR datasets, performs automated analyses 
on the different types of NMR experiments and conducts 
consistency checks. CMC-q uses a 1H-NMR spectrum and 
the corresponding structure file of the fragment for struc-
ture verification. Further, using the advanced options, the 
user can customize and define signals of solvent or known 
impurities that should not be considered within the struc-
ture verification process. In order to confirm the integrity 
of the fragments, 1H-NMR spectrum of the individual frag-
ments with a final approximate concentration of 1 mM in 
d6-DMSO were acquired. Further, within the drug discovery 
process, it is also important to have a good idea about the 
concentration of the ligand in the sample. Several quantita-
tive NMR methods have been described within the literature 
(Holzgrabe 2010). In general, by NMR the concentration 
of the substance is determined relative to the known con-
centration of a standard. We used 1 mM of 1,4-dioxane as 
an external standard and defined the integral of the signal 
as Eretic Reference (Hoult 2000; Hoult and Richards 2011; 
Wider and Dreier 2006) in CMC-q. After acquisition of each 
spectrum, the analysis, consistency check with the structure 
and concentration determination is performed “on-the-fly” 
at the spectrometer.
Solubility and retaining integrity of the fragments in the 
aqueous buffer is an important requirement for performing 
ligand-detected NMR screening experiments. Especially, 
hydrolysis-induced degradation in an aqueous buffer may 
be overlooked if the QC was solely limited to DMSO solu-
tions. For the solubility analysis our typical NMR samples 
contained ~ 1 mM compound in 50 mM Sodium phosphate 
buffer at pH 7.4, 150 mM Sodium chloride, 90%  H2O/10% 
 D2O and 1 mM of 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid 
sodium salt (TMSP-Na) added as an internal chemical shift 
reference and quantification standard.
Automated analysis by CMC-a yields a graphical display 
representing the analysis results of the whole fragment col-
lection (Fig. 2a). This compact representation of the result 
displays the consistency of the spectra with the structure 
and also the concentration. For a given fragment a green 
colored circle indicates “consistent”, a red for “inconsist-
ent” and the size of the circles indicate the concentration. 
An automated analysis resulted in approximately 65% of 
the fragments as consistent and 35% as inconsistent both in 
DMSO and buffer. Further, approximately 60% of the frag-
ments displayed exactly overlapping (consistent/inconsist-
ent) results between the DMSO and buffer measurements. 
In an effort of identifying false negatives, we performed a 
manual analysis over a subset of the “inconsistent” frag-
ments and found that approximately 30% additionally turn 
consistent. Most often either compound signal overlap with 
the solvent, missed peak picking or incorrect integrals were 
the reasons for the failure of automated analysis. For exam-
ple, the methyl group signal of a compound in d6-DMSO 
appears at 3.4 ppm, however, is not resolved due to a overlap 
with the water signal (Fig. 2b, bottom). Moreover, this sig-
nal (3.2 ppm) is resolved when measured in buffer (Fig. 2b, 
top). Further, LC–MS data for the compound also revealed 
that the fragment stock is 100% pure and has the expected 
molecular mass. However, in an effort to identify the false 
positives, < 1% of the fragments turned into inconsistent sug-
gesting that the automated analysis performed by CMC-a 
is robust.
Integration of methods to eliminate 
the inconsistent fragments from the library
In general, it is quite common to observe that a significant 
proportion (between 15 and 40%) of the fragments fail in 
the QC process (Keseru et al. 2016; Lau et al. 2011). A 
critical analysis of the QC data obtained from NMR-based 
automated analysis and LC–MS provides insights into some 
of the potential causes. We found that most often the reason 
for QC failure was degradation (Fig. 3a, b), compromised 
purity, inconsistency with the structure and insolubility or no 
compound. In couple of instances we observed mixtures of 
compounds (Fig. 3c, d), though they were located two wells 
apart in the same plate. This probably would have occurred 
during the manual assembly of the library. Another chal-
lenge we faced was the inconsistency of the results between 
NMR and LC–MS based QC. LC–MS of the fragment clas-
sifies it as not pure (Fig. 3b, g, h), however, the NMR spectra 
of the same, both in DMSO and also in buffer shows that it 
is consistent with the structure. Another frequent reason to 
fail the QC is insolubility of the fragments or no compound 
or very little compound in the stock (Fig. 3e, f). In general, 
we adopted an optimized workflow protocol scheme (Fig. 4) 
in order to streamline the elimination of inconsistent frag-
ments from the library. Initially, an automated analysis is 
performed by CMC-a, which results in two classifications 
(consistent-auto; inconsistent-auto). In order, to have a sec-
ond layer of quality check for those consistent fragments, we 
then perform a manual assessment of peak patterns between 
the DMSO and buffer spectra (compare DMSO vs buffer). 
If they are similar, then they enter into the green zone of the 
workflow and if not, then will enter into the manual interven-
tion workflow. Approximately, 30% of the fragments were 
discarded.
Speed and periodic evaluation 
of the fragment library
In general, long term stability of the fragment library is an 
important requirement for performing several screening 
campaigns. Therefore, periodic evaluation of the fragment 
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library in terms of its quality is indispensable. In order to 
economically meet these objectives, we took the advantage 
of the latest state-of-the-art advanced hardware viz., the 
Bruker robot system SamplePro Tube™, with which the 
liquid sample collection can be filled into the 3 mm NMR-
tubes in an automated manner. 1H NMR spectra are then 
collected at 298 K using a 600 MHz Bruker Avance III HD 
NMR spectrometer equipped with triple resonance 5 mm 
TCI Prodigy cryogenic probe and a sample changer Sam-
pleJet™, which can handle more than 500 samples in a go. 
This together with software tools of Bruker, like CMC-q 
and CMC-a speeds up the data acquisition and analysis. 
Fig. 2  Quality control of the fragments. a Screenshot of the graphical 
display representing the CMC-a based analysis of 358 fragments in 
a compact form. This window displays the determined concentration 
and structural consistency (green means consistent; red means incon-
sistent, blue indicates technical complications, light colors-results 
from automation, intense colors-results from manual analysis). If the 
additional option to show the concentration is checked, then the sizes 
of the displayed circles are proportional to the value. Samples within 
the range of the expected concentration have a white background. 
b1H-NMR spectrum of a fragment acquired in buffer (blue, top) and 
in d6-DMSO (red, bottom). The proton signal overlapped by the water 
signal in the red spectrum gets resolved in the blue spectrum
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Fig. 3  Example spectra of fragments. a Degradation of fragment, b degradation of fragment as seen in 1H-NMR and contradiction between 
NMR and LC–MS results, (c, d) impurities, (e, f) too little compound, (g, h) passing NMR, but fails in LC–MS
Fig. 4  Schematic representa-
tion of the workflow during the 
stringent quality control of the 
iNEXT fragment library
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Typically, for a fragment library comprising of around 
782 fragments complete QC could be completed within a 
span of 3 to 4 days. Maintenance of the library also implies 
replacing fragments that turn out to be unstable. Storage of 
the fragment solutions in matrix tubes instead of deep-well 
plates is therefore preferred.
Conclusions
The progression of drug discovery within academia has 
shown significant maturity and has imbibed FBDD as a more 
commonly utilized approach. Challenges faced in academic 
FBDD have been significantly overcome with more consor-
tium-based organizations, such as the iNEXT. Within this 
framework, assembly of a robust fragment library, perform-
ing periodic QC and allowing the library to evolve can be a 
demanding task. We through a set of examples and advanced 
methods have demonstrated the ease with which one can 
perform the QC in an academic setting. In general, an inte-
grated choice of methods, viz., NMR, LC–MS together with 
software assisted validation of a fragment library ensures a 
relatively high quality of fragments assessed for its integ-
rity, solubility and also stability to endure several screening 
campaigns.
Methods
Sample preparation
The fragments were stored as 50 mM stock solutions in a 
mixture of 90% d6-DMSO and 10%  D2O. 1H-NMR spectrum 
of the individual fragments with a final approximate concen-
tration of 1 mM in d6-DMSO /Phosphate buffer pH 7.4 were 
acquired. The final sample volume was 170 μL with 5%  D2O 
as locking solvent in a 3 mm NMR tube.
NMR spectroscopy
Spectra acquisition was carried out on a Bruker AVII-
IHD-500/600 NMR spectrometer. The fully automated 
acquisition of the data was performed by using Bruker 
CMC-q software interface within Topspin. The default 
parameter sets provided within the software were used for 
acquisition of the data at 298 K. All analysis were performed 
using Topspin 4.0 with CMC-a addon.
LC–MS
HRMS‑instrument
Agilent Technologies 6230 Accurate Mass TOF LC/MS con-
nected to Agilent Technologies HPLC 1260 Series; Column: 
Thermo Accucore aQ; particle size: 2.6 µM Dimension: 
100 × 2.1 mm; Eluent A:  H2O with 0.1% formic acid Elu-
ent B: MeCN with 0.1% formic acid; conditions: 0.00 min 
95% A, 0.2 min 95% A, 2.1 min to 1% A as gradient, 4 min 
as Stoptime, 1.5 min Posttime for reconstitution. Flow rate: 
0.4 ml/min; UV-detection: 220 nm, 254 nm, 450 nm. Injec-
tion volume: 1 µl.
For MS analysis compounds were dissolved in 20 mM 
DMSO and plated on a 384 well plate, 0.5 µl aliquot was 
taken, diluted with acetonitril/water (1:1, 80 µl) to a con-
centration of 125 μM and filtered with a Whatman® 384 
well plate (0.45 μm hydrophilic PVDF) before measurement. 
The UV purity was determined based on the absorption at 
254 nm.
Fragment library and the NMR software
The iNEXT fragment library (DSiP-library) can now be pur-
chased from Enamine (https ://enami ne.net/fragm ents/plate 
d-libra ries/dsi-poise d-libra ry). All Bruker software includ-
ing CMC-a can be downloaded from the Bruker web page.
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